WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 6'3901 Infant (under 12 months) mortality rate: 142
GDP / capita (US$): 11'7751 Child (under 5 years) mortality rate: 182

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 30'376  29'988  29'615  29'263  28'934  26'000  21'772  17'329 
Births 599  600  602  603  605  626  651  621 
Surviving infants 589  590  591  592  593  605  611  564 
Pop. less than 5 years 2'924  2'925  2'927  2'932  2'937  3'006  2'971  2'724 
Pop. less than 15 years 8'739  8'746  8'758  8'777  8'790  8'862  8'333  7'263 
Female 15-49 years 8'082  7'980  7'878  7'775  7'684  6'758  5'372  4'031 

Number of reported case

(Click for retrospective incidence data for Peru)
Diphtheria 44  185 
Japanese encephalitis
Measles 737  19'246 
Mumps
Pertussis 1'373  1'173  56  64  254  68  1'134  12'134 
Polio* 182 
Rubella
Rubella (CRS)
Tetanus (neonatal) 10  93  294 
Tetanus (total) 35  17  38  47  19  57  124  525 
Yellow fever 21  13  18  17  30 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Peru)
Vaccine year result method % card seen                                                
BCG 2011  94  DHS   81  95  95  91  95  97  93  83  57 
DTP1 2011  93  DHS   81  97  100  94  97  99  91 
DTP3 2011  83  DHS   81  88  95  91  93  92  98  72  16 
HepB_BD          82  81  76  74  71  41 
HepB3          88  95  91  93  92  44 
Hib3          88  95  91  93  92  38 
JapEnc         
MCV 2011  90  DHS   81  85  94  96  94  91  64  23 
MCV2          54  63  70  57  42  97 
PCV1          97  100  97  95  66 
PCV3          85  89  82  83 
Pol3 2011  86  DHS   81  71  94  91  92  92  93  73  16 
Rota1          95  98  90  89  59 
Rota_last          86  91  84  75  41 
Rubella1          85  94  96  94  91 
TT2plus 2004  53  DHS   68  41  43  42  49  84 
PAB         
VAD1          99*  50 
YFV          64  58  51  61  66 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Peru)
BCG 95  95  91  95  97  93  83  57 
DTP1 97  99  94  97  97  99  89  39 
DTP3 88  95  91  93  93  98  72  16 
HepB3 88  95  91  93  93 
HepB_BD 82  81  76  74  71 
Hib3 88  95  91  93  93  43 
MCV 85  94  96  94  91  97  64  23 
MCV2 54  63  70  56  42 
PAB 85  85  85  85  67  66  19 
PCV3 85  89  82  83 
Pol3 71  94  91  92  92  93  73  16 
Rota_last 86  91  84  75  41 
YFV 64  58  51  61  66 

Number of districts in the country 1'838  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 31
From 80 to 89% 11
From 50 to 79% 37
Less than 50% 21
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 4, 6 months; Yes pertussis contrindication
DTwP 18 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HIB Yes 12 hours
HepB birth; Yes and adults in risk groups
IPV 2, 4 months; Yes
Influenza 6-23 months (x2 doses): >= 65 years; Yes and risk groups
MMR 12, 18 months; Yes
OPV 6, 18 months; 4 years Yes
Pneumo_conj 2. 4, 12 months; Yes
Rotavirus 2, 4 months; Yes
TT sz contact; +2, +8 months;
Td 1st contact; +2, +8 months; Yes
VitaminA from 6 months; No priority districts
YF 15 months; Yes population at risk zones

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number     2011-2015  2006-2010 y 2011-2015  2007-2012  2008 - 2012   
Nº of districts with microplans that include activities to raise immunization coverage number     1'834  1'834  1'834  1'833  34 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 1'838  1'838  1'834  1'834  1'834  1'833  1'833 
Nº districts with DTP3 coverage >=80% number 774  886  862  951  992  1'391  274 
% of districts with DTP3 coverage >=80% From 0 to 100% 42  48  47  52  54  76  15 
Nº districts with measles (MCV1) coverage >=95% number 501  596  658  726  613  806   
% of districts with MCV1 coverage >=95% From 0 to 100% 27  32  36  40  33  44   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100  100 

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.